Tiagabine (Gabitril)

A nipecotic acid derivative that acts as a GABA uptake inhibitor and anticonvulsant agent. It is used in the treatment of EPILEPSY, for refractory PARTIAL SEIZURES.

Also Known As:

Gabitril; (R)-(4,4-bis(3-Methyl-2-thienyl)-3-butenyl)-3-piperidinecarboxylic acid, Hydrochloride; N-(4,4-di(3-Methylthien-2-yl)but-3-enyl)nipecotic acid; NO 328; NO 329; NO-328; NO-329; Tiagabine Hydrochloride; Tiagabine, (S)-isomer; 3-Piperidinecarboxylic acid, 1-(4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl)-, (3R)-

Networked: 386 relevant articles (73 outcomes, 108 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - Nipecotic Acids
      - Tiagabine: 386
- Heterocyclic Acids
  - Nipecotic Acids
    - Tiagabine: 386

Experts

1.	Luszczki, Jarogniew J: 8 articles (02/2012 - 01/2004)
2.	Marson, Anthony G: 6 articles (10/2019 - 01/2009)
3.	Kälviäinen, Reetta: 6 articles (09/2016 - 12/2005)
4.	Czuczwar, Stanisław J: 6 articles (07/2015 - 05/2003)
5.	Sałat, Kinga: 5 articles (06/2021 - 01/2012)
6.	Perucca, E: 5 articles (12/2001 - 05/2000)
7.	Clausen, Rasmus P: 4 articles (07/2020 - 05/2009)
8.	Schousboe, Arne: 4 articles (07/2020 - 08/2002)
9.	White, H Steve: 4 articles (07/2020 - 08/2002)
10.	Czuczwar, Mirosław: 4 articles (05/2009 - 05/2003)

Related Diseases

1.	Seizures (Absence Seizure) 03/01/1998 - "The percentage of patients achieving an increase of at least 50% in the proportion of days free of all partial seizures was significantly greater in the tiagabine group compared to placebo (14 versus 4%, P<0.01). " 03/01/1998 - "The present study shows that tiagabine, at a dose of 10 mg administered three-times daily, which is at the lower end of the usual recommended dose range (30-50 mg/day, tiagabine base), is generally well tolerated and demonstrates efficacy for the treatment of refractory partial seizures." 07/01/1997 - "tiagabine) in that enhanced efficacy against MES and reduced efficacy against kindled seizures is observed. " 03/01/2005 - "Efficacy and tolerability of tiagabine was evaluated in patients with non-controlled partial seizures in a multicentre, open-label, parallel group study. " 12/01/1998 - "Conversion to tiagabine monotherapy has been also possible in substantial amount of patients with partial seizures in three trials. "
2.	Epilepsy (Aura) 04/01/2002 - "In two cases, adjunctive tiagabine was effective in the management of both epilepsy and severe impulse control disorder. " 01/01/2000 - "Tiagabine appeared to be an effective and safe drug in resistant epilepsy in children below 12 years of age." 08/25/2004 - "Recent electrophysiological and behavioral studies indicated that the new anti-epileptic drug, tiagabine, is functional in globus pallidus, which may present more information to understand the involvement of globus pallidus in epilepsy." 12/01/2000 - "Tiagabine showed efficacy mainly in localisation-related syndromes and was well tolerated by most children in a group of very refractory patients and warrants further study in children with epilepsy." 08/01/1998 - "In two open-label long-term safety studies, we determined tiagabine (TGB) pharmacokinetics in patients with epilepsy. "
3.	Partial Epilepsies (Epilepsy, Partial) 08/01/1999 - "Tiagabine (TGB) is effective in patients with focal epilepsies. " 01/01/1997 - "A dose-response trial that tested the efficacy of tiagabine monotherapy in patients with refractory partial epilepsy was uninformative. " 06/01/2006 - "The results of this small open-label extension study indicate that patients with chronic partial epilepsy who were successfully converted to long-term tiagabine monotherapy demonstrated no adverse effects on cognitive function or mood." 06/01/2006 - "The long-term effects of tiagabine monotherapy on cognition and mood were evaluated in adult patients with chronic partial epilepsy in a 48-week, open-label extension period that followed an 8-week, double-blind, titration study. " 06/01/2001 - "We did an open multicentric study, in Spain, in which patients with partial epilepsy treated with one or more drugs were also given tiagabine. "
4.	Pain (Aches) 12/01/2001 - "Pain symptoms and quantitative sensory test results improved with treatment, especially at low doses of tiagabine (4-8 mg). " 12/01/2001 - "Low doses (4-8 mg) of tiagabine reduced pain symptoms by 16-38%, improving surface pain (37.5%), skin sensitivity (32.8%), burning (38.6%), cold (25.4%) and pain sharpness (29%; p <0.03). " 12/01/2001 - "Weeks 1-4: Dose of tiagabine was increased weekly by 4 mg orally up to 16 mg in week 4. Quantitative sensory testing for vibration, cooling, and heat-pain, and quantitative sudomotor axon reflex test (QSART) were done at week 0 and week 4. The McGill Pain Questionnaire was administered weekly. " 01/01/2005 - "Tiagabine may reduce bruxism and associated temporomandibular joint pain." 08/01/2009 - "If the results from this study could be extrapolated to clinical settings, the combination of tiagabine with gabapentin might be beneficial in the pain relief in humans."
5.	Bipolar Disorder (Manic Depressive Psychosis) 12/07/2011 - "The main outcomes to be assessed were:(1) the efficacy of tiagabine treatment in preventing or attenuating further episodes of bipolar disorder, including its efficacy in rapid cycling disorder; (2) the acceptability of tiagabine treatment to participants; (3) the prevalence of side effects; and (4) mortality, if any, on tiagabine treatment.Outcomes" 09/01/2002 - "Three published studies have addressed the use of tiagabine for bipolar disorder (BPD); two described positive results and one negative results. " 10/01/2002 - "Open add-on tiagabine for treatment-refractory patients with bipolar disorder demonstrated limited efficacy with the majority of patients showing no change or worsening of clinical symptoms. " 12/12/2012 - "We found no randomised controlled trials of tiagabine in the treatment of acute episodes of bipolar disorder. " 12/12/2012 - "Randomised controlled trials, which compared tiagabine with placebo or with active agents in the treatment of any acute mood episodes in bipolar disorder in adults, male and female, aged 18 to 74 years. "

Related Drugs and Biologics

1.	Gabapentin (Neurontin)
2.	Topiramate (Topamax)
3.	Anticonvulsants (Antiepileptic Drugs)
4.	Vigabatrin
5.	Oxcarbazepine (Trileptal)
6.	Lamotrigine (Lamictal)
7.	Felbamate (Felbatol)
8.	gamma-Aminobutyric Acid (GABA)
9.	Phenobarbital (Luminal)
10.	Levetiracetam (Keppra)

Related Therapies and Procedures

1.	Therapeutics
2.	Vagus Nerve Stimulation
3.	Relaxation Therapy (Relaxation Technique)
4.	Psychology Biofeedback (Biofeedback)
5.	Drug Therapy (Chemotherapy)